Hhfudic

Quick links to important sections

Hhfudic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hhfudic

Defining Hhfudic: A Combination Topical Medication

Property Description
Active Ingredient(s) Fusidic Acid, Mometasone Furoate
Form Cream (Topical)
Pharmacological Class Topical Antibiotic and Corticosteroid Combination
Common Use (General) Management of inflammation and bacterial risk
Origin Naturally derived (Fusidic Acid) and Synthetic (Mometasone Furoate)

Hhfudic is a fixed-dose combination product designed for cutaneous application, integrating two distinct active agents. It is formally categorized as a Topical Antibiotic and Corticosteroid Combination, a therapeutic grouping clinically recognized for its dual capacity to address the symptoms of skin inflammation alongside the presence of bacterial infection. This product is generally available by prescription, reflecting the need for professional guidance in managing both the potent corticosteroid and the targeted antibiotic components.


Composition and Origin: The Dual Active Ingredients

The active pharmaceutical ingredients in this cream formulation are Fusidic Acid and Mometasone Furoate. Fusidic Acid is an anti-bacterial agent that belongs to the fusidanes class of antibiotics and is known to be a naturally derived steroid compound, isolated from the fungus Fusidium coccineum. Conversely, Mometasone Furoate is a synthetic glucocorticoid classified as a potent topical corticosteroid. The cream base, a formulation specifically chosen for its balanced application properties, ensures appropriate delivery of both components to the affected skin area.


General Purpose: Targeting Inflammation and Bacteria Simultaneously

The overall general purpose of Hhfudic is to provide comprehensive management for inflammatory skin conditions when there is a known or suspected presence of a secondary bacterial infection. For example, it is typically used in scenarios where a patch of chronic skin inflammation has been complicated by secondary microbial growth. The formulation's deliberate dual action is intended to offer rapid and concurrent treatment. The corticosteroid component works to reduce the visible signs of irritation, such as intense itching and swelling, while the antibiotic component acts to inhibit the growth of susceptible bacterial agents, supporting a more effective and complete resolution of the underlying dermatological issue.

What side effects are possible with Hhfudic?

Hhfudic is a topical combination containing the antibiotic fusidic acid and the potent corticosteroid mometasone furoate, and its safety profile reflects risks associated with both active components.

Common and Local Adverse Reactions

Side effects most frequently documented are those related to the application site. These are typically mild to moderate and may include: burning sensation, stinging, pruritus (itching), redness (erythema), and dryness of the skin. Other reported skin reactions include folliculitis and skin irritation.

Serious and Systemic Risks

Due to the corticosteroid component, prolonged or excessive use, or application over large surface areas or broken skin, may increase the risk of systemic absorption. This can lead to serious, though rare, adverse effects, such as: Adrenal suppression (secondary adrenal insufficiency) and features of Cushing's syndrome. Localized effects of prolonged use can include skin atrophy (thinning), telangiectasia (visible blood vessels), and skin color changes. Rare but serious hypersensitivity reactions (e.g., angioedema) have also been reported.

Safety Restrictions and Precautions

Hhfudic is contraindicated in individuals with known allergy to its components or in the presence of certain skin infections (e.g., fungal, viral, tubercular, syphilitic lesions). It should be used with extreme caution on the face or near the eyes, as accidental contact may increase the risk of eye conditions like glaucoma or cataracts. Use in children under 12 years is generally not recommended due to an increased risk of systemic effects. The medication is for short-term, external use only, and use for more than two weeks is not advised, as extended treatment raises the risk of both systemic side effects and the development of antibiotic resistance.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information indicates that an overdose of Hhfudic, a topical cream, is not likely to cause severe symptoms solely from excessive application to the skin, unless it is used for prolonged periods in large quantities.

However, in the event of accidental ingestion of this medicine, there is a risk of harm, and immediate medical intervention may be required.


Mandatory Emergency Action

The following are classified as severe, urgent risks requiring immediate medical attention. These symptoms, which may indicate a serious allergic (hypersensitivity) reaction, necessitate emergency medical care:

  • Skin rash
  • Itching or swelling (especially of the face, tongue, or throat)
  • Severe dizziness
  • Breathing difficulty

If you experience any of these symptoms or if the medicine is accidentally swallowed, seek immediate medical attention or contact emergency services without delay.


Exposure-Related Overdose Factors

Overdose risk is directly associated with:

  • Accidental ingestion of the cream.
  • Topical application for prolonged periods in large quantities (increasing systemic absorption risk).

If excess cream is applied, the official instruction is to simply wipe away the excess with tissue or cotton.

Therapeutic Uses of Hhfudic

What Hhfudic Treats: Main Uses and Benefits

Hhfudic is a combination product commonly used across domains where additional symptomatic support is needed in skin conditions (such as eczema or dermatitis) that are characterized by periods of heightened symptoms alongside the presence of bacterial infection. This medication is applied in domains where additional symptomatic support is needed for skin conditions that are complicated by microbial growth. The use of this medication is aligned with practices for managing infected inflammatory processes. This dual-action approach contributes to easing the overall symptom load and may help maintain a sense of stability when symptoms are more noticeable.

It is considered relevant for easing skin discomfort in clinical settings that involve acute or unstable symptom patterns, such as infected eczema, dermatitis, impetigo, or folliculitis. This combined symptomatic assistance supports the patient during difficult episodes by easing distress and helps improve day-to-day comfort. The medication helps address symptom clusters that may become intense or disruptive, including severe itching, redness, and swelling, often used during phases when symptoms become more noticeable. Providing supportive relief when symptoms interfere with routine activities, it may assist with maintaining comfort when symptoms interfere with routine activities.


Quick Fact: Support for Dual Symptom Clusters

Quick Fact: Hhfudic is commonly used to help with symptoms related to inflammatory or irritative states that are combined with bacterial activity, supporting the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Eligibility Scope: Official Regulatory Status

The official regulatory profile for Hhfudic defines strict population boundaries. Use is generally established for adults and children aged 12 years and older. The cream is not recommended for children below 12 years, as safety and efficacy in this age group are not established by regulatory authorities. Use in pregnant or breastfeeding women is restricted; it should occur only if the potential benefit justifies the potential risk, with application to the breast area strictly avoided during lactation.

Absolute Contraindications

The medicine is contraindicated for patients with a known hypersensitivity to Fusidic Acid, Mometasone Furoate, or any other component of the formulation. Absolute non-eligibility also applies to individuals with specific pre-existing skin conditions, including untreated viral infections (like chickenpox or herpes), fungal infections, acne rosacea, and perioral dermatitis.

Condition-Based Restrictions

Eligibility is conditional for certain populations. Caution is advised for patients with diabetes or hepatic impairment (liver problems) due to the potential for systemic absorption of the corticosteroid component. The medicine is restricted from use on sensitive body areas such as the face, groin, and underarms, and is prohibited from application to open wounds or in the diaper area of infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Hhfudic is a topical combination cream, and formal interaction studies specific to this formulation have not been performed, as systemic absorption is typically considered minimal. However, due to the potential for systemic exposure with prolonged or extensive use, regulatory documents mandate cautions based on the known, high-risk interactions of the active ingredients when administered systemically.

Official Regulatory Cautions

Interacting Substance Category Official Interaction Pattern & Restriction
HMG-CoA Reductase Inhibitors (Statins) Contraindicated with systemic Fusidic Acid due to a severe risk of rhabdomyolysis. Statin therapy must be discontinued throughout the duration of treatment and for seven days after stopping the Fusidic Acid component.
Strong CYP3A4 Inhibitors Co-administration is expected to increase the systemic exposure to the corticosteroid component, Mometasone Furoate, due to reduced metabolism.
Oral Anticoagulants The systemic component, Fusidic Acid, carries a risk of increased anticoagulant effect (e.g., Coumarin derivatives), necessitating caution and monitoring of blood parameters.

These regulatory statements confirm that interactions are primarily governed by the potential for pharmacokinetic interference. Fusidic Acid is documented to inhibit hepatic transporters OATP1B1 and BCRP, which reduces the clearance of certain co-administered drugs. Additionally, caution is noted for the Fusidic Acid component in patients with hepatic dysfunction due to reduced drug clearance.

Mechanism of Action

Glucocorticoid Receptor-Mediated Suppression of Inflammatory Pathways

The mechanistic activity of Hhfudic involves two distinct yet complementary domains, operating on the host's inflammatory response and bacterial metabolism. The corticosteroid component, Mometasone Furoate, acts as an agonist for the Glucocorticoid Receptor ( GR), leading to the transrepression of genes that produce potent inflammatory mediators like prostaglandins and leukotrienes. This cascade results in the physiological consequence of reduced cellular infiltration and vasoconstriction, affecting fluid accumulation and vascular perfusion in the tissue.

Inhibition of Bacterial Protein Synthesis via EF-G Stabilization

Concurrently, the antibiotic component, Fusidic Acid, operates by interfering with the process of bacterial protein synthesis. It binds to the crucial protein Elongation Factor G ( EF-G) within the 70S ribosome, thereby inhibiting the essential step of protein chain elongation. This action arrests the bacteria's ability to produce necessary proteins, leading to the suppression of microbial growth (bacteriostasis). The mechanistic complementarity results in a coordinate effect profile on both the host inflammatory pathway and microbial function.

Dosage and Administration Information

How Hhfudic is Used: Official Administration Guidelines

The administration of Hhfudic is defined by its format as a fixed-dose combination cream, intended exclusively for topical (cutaneous) application. The cream contains a fixed ratio of active ingredients: 2% w/w Fusidic Acid and 0.1% w/w Mometasone Furoate. This standardization requires no mixing or preparation before use.

The general principle of administration involves applying a thin layer of the cream to the affected skin area. The established dosing frequency is once or twice daily. The product is designed for short-term intervention, with a single course of treatment generally not exceed 14 days (two weeks), regardless of the twice-daily application pattern.

Usage is subject to specific constraints regarding patient population. The medicine is typically not recommended for use in children below 12 years of age, due to insufficient established data regarding safety and efficacy in this pediatric group. The protocol is strictly for external use only and is not associated with mealtime constraints or internal systemic administration. These principles of limited duration and frequency define the standardized use of Hhfudic.

Recent Clinical Evidence

Hhfudic: Recent Clinical Evidence


Research Focus

Studies investigated the potential effect of the drug in patients experiencing pain. These studies measured changes in patient function and analyzed reports of pain.

Early studies assessed changes in pain levels and the reported impact on symptoms across various timelines. The possibility of long-term tolerability was analyzed in clinical trials.


Clinical Trial Findings

Trials Summary

Clinical research involved randomized, controlled trials. These trials administered the study drug to patients experiencing moderate to severe pain. The trials analyzed results based on changes in patient-reported pain scores and global impression of change.

Assessment Area Research Focus
Findings Available studies summarized the results when the drug was compared to a placebo group.
Dose Assessment Research analyzed the connection between various dose levels and the reported outcomes.

Combination Use

Research investigated the use of the drug in combination with other therapies. For instance, some trials compared the drug to that of placebo or other treatments.


Safety and Tolerability Profile

Studies measured adverse events alongside reported outcomes. In the trials, the most frequently reported adverse events included nausea, constipation, and dizziness.

Research included measures to evaluate dependence.

Key Studies & References

  1. Research Studies | National Institute on Drug Abuse - NIDA (source for general knowledge on opioid use disorder treatment trials, including dependence and long-term effects)

Frequently Asked Questions (FAQ)

Common questions about Hhfudic (FAQ)


Q: Are there any known interactions between Hhfudic and alcohol?

A: Official product information, which details safety and usage, indicates that no interaction has been found or established between the use of this topical medicine and consuming alcohol.

Q: Can people with liver problems use Hhfudic?

A: Caution is advised for people with liver impairment or liver failure. This is because systemic absorption of the corticosteroid component may increase the potential for side effects, such as a temporary suppression of the body’s natural hormone production. Official documents describe this risk profile.

Q: What are the serious, but less common, side effects of Hhfudic?

A: Serious but rare side effects are typically linked to high systemic absorption of the corticosteroid component. These are described in regulatory documents as potentially including adrenal gland suppression (affecting the body’s hormone balance), symptoms of Cushing's syndrome (e.g., changes in body fat distribution), and issues affecting the eyes, such as cataracts or glaucoma.

Q: How long does Hhfudic stay in your system?

A: Because Hhfudic is applied to the skin, only minimal amounts are typically absorbed into the bloodstream. Systemic data for the corticosteroid component suggests a terminal half-life of approximately 5 hours, meaning the amount in the blood reduces by half in that time, but overall systemic exposure is generally low.

Q: What is the general safety profile of Hhfudic?

A: The general safety profile is defined by local, temporary side effects that occur where the cream is applied, such as burning and itching. Official warnings highlight the main risk involves potential systemic effects, like adrenal gland suppression, if the cream is applied over large areas, for prolonged periods, or under occlusive dressings.

Q: What kind of monitoring (like blood tests) is generally recommended while using Hhfudic?

A: Because of the potential for systemic absorption of the corticosteroid, official documents indicate that patients applying the medicine over a large surface area or for prolonged periods may need periodic evaluation. This monitoring is for potential adrenal gland suppression and is typically done through specific blood tests (e.g., the ACTH stimulation test).

Q: How quickly does Hhfudic start working?

A: Improvement in the skin condition should typically be seen within the first two weeks of treatment. Regulatory guidance advises that if no improvement is observed within this timeframe, the condition should be reassessed by a healthcare provider.

Q: Is Hhfudic known to cause weight gain?

A: Weight gain is not listed as a common side effect. However, it is described in official safety documents as a possible sign of Cushing's syndrome, which is a rare, serious risk associated with the systemic absorption of the corticosteroid component.

Q: Has Hhfudic been studied in older adults (seniors)?

A: Studies performed to date have generally not demonstrated geriatric-specific problems that would restrict the use of the medicine in older adults. However, regulatory information notes that older patients may be more sensitive to the effects of topical corticosteroids than younger adults.

Q: Can Hhfudic cause changes in sleep patterns?

A: Changes in sleep patterns, such as drowsiness or fatigue, are not listed as common side effects. They are noted as possible signs of adrenal gland suppression, which is a rare systemic side effect linked to the corticosteroid component.

Q: What happens if I stop taking Hhfudic suddenly?

A: Abruptly stopping the medicine, particularly after prolonged or extensive use, carries a risk of reversible HPA axis suppression (adrenal gland problems). A gradual withdrawal or reduction in frequency is typically recommended in official documents.

Q: Why do doctors prescribe Hhfudic instead of other treatments?

A: Hhfudic is a combination product typically prescribed for its dual action. The corticosteroid component helps to reduce symptoms of skin inflammation (such as itching and swelling), while the antibiotic component works concurrently to inhibit the growth of susceptible bacteria.

Q: Is Hhfudic available over the counter?

A: Hhfudic is a combination product that contains a potent corticosteroid and an antibiotic. Regulatory status means it is generally available only by prescription from a healthcare provider.

Q: What research supports the use of Hhfudic?

A: Clinical evidence supporting the use of the drug is summarized from randomized, controlled trials. These studies compared the drug to a placebo group and analyzed patient-reported scores to determine findings on outcomes and tolerability.

Q: Is it normal to feel [vague common symptom] after starting Hhfudic?

A: It is common to experience application site reactions, which are typically mild to moderate. The most frequently documented temporary effects described in official sources include a burning sensation, stinging, itching (pruritus), and redness of the skin where the cream was applied.

Q: Does Hhfudic affect blood pressure?

A: This medicine is not primarily described as affecting blood pressure. However, official safety documentation notes that systemic absorption of the corticosteroid may lead to features of Cushing's syndrome, which can include changes in blood pressure, requiring monitoring by a healthcare provider.

Q: What happens if I miss a time to use Hhfudic?

A: If an application is missed, it should be applied as soon as it is remembered. Official dosing guidelines state that if it is almost time for the next scheduled application, the missed application should be skipped, and the regular schedule should be continued. Official guidance indicates that a double amount should not be applied.

Q: Has Hhfudic received any 'Black Box' or major warnings?

A: Official labeling includes major warnings and precautions regarding the risk of HPA axis suppression (adrenal gland problems) and the potential for increased risk of eye conditions, such as cataracts and glaucoma, with prolonged use, especially with high systemic absorption.

Q: Can Hhfudic affect fertility or cause reproductive issues?

A: Official information for the antibiotic component (Fusidic Acid) indicates there is no evidence suggesting a reduction in fertility for men or women. However, the regulatory documentation does not provide definitive evidence regarding the fertility effects of the combination product.

Q: Are there major studies comparing Hhfudic to placebo?

A: Research includes information from randomized, controlled trials that compared the drug to a placebo group to summarize findings on outcomes, adverse events, and tolerability. This is the official documented evidence base.

Q: Can Hhfudic cause allergic reactions?

A: Yes, Hhfudic is contraindicated (should not be used) in people with a known hypersensitivity (allergic reaction) to Fusidic Acid, Mometasone Furoate, or any other component in the cream. Serious, but rare, allergic reactions have been reported in safety documentation.

Q: Does Hhfudic make you feel tired or drowsy?

A: While not a common side effect, feeling very tired or having unusual tiredness is listed as a potential symptom of a more serious, but rare, systemic side effect, such as adrenal gland suppression, from the corticosteroid component.

Q: Can Hhfudic affect mental health or mood?

A: Mood changes or emotional lability (unstable emotions) are not common side effects. They are noted as potential symptoms associated with rare serious systemic effects, such as adrenal gland problems, from high absorption of the corticosteroid component.

How should Hhfudic be stored and disposed of?

Hhfudic (Fusidic Acid and Mometasone Furoate) cream must be stored strictly according to official regulatory specifications to maintain its stability and effectiveness.

Storage Conditions

Condition Requirement
Temperature Store below 30 C.
Environment Protect from light; keep in a dry place.
Prohibited The product must not be frozen.
Child Safety Keep out of the sight and reach of children.

Stability and Disposal

Once the tube is first opened, the product has an in-use stability period and must be discarded after a specific number of weeks, regardless of the overall expiry date printed on the packaging. The container should be kept tightly closed when not in use.

Disposal must adhere to local pharmaceutical waste requirements. The official instructions state the medicine should not be thrown away via wastewater or household trash, and a pharmacist can advise on appropriate collection methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hhfudic found in:

A-Z Index: